CRISPR Therapeutics AG (CRSP) Current Deferred Revenue (2016 - 2026)

CRISPR Therapeutics AG has disclosed Current Deferred Revenue across 10 years of filings, most recently posting $15.3 million for Q1 2026.

• Current Deferred Revenue for Q1 2026 came in at $15.3 million, up 407.91% year-over-year; the trailing twelve-month figure through Mar 2026 was $15.3 million (up 407.91% YoY), and the FY2025 annual result was $15.8 million, up 310.17% from the prior year.
• Current Deferred Revenue came in at $15.3 million for Q1 2026 at CRISPR Therapeutics AG, down from $15.8 million in the prior quarter.
• In the past five years, Current Deferred Revenue ranged from a high of $15.8 million in Q4 2025 to a low of $1.3 million in Q3 2025.
• The 4-year median for Current Deferred Revenue is $4.1 million (2024), against an average of $6.4 million.
• Across the five-year window, Current Deferred Revenue slumped 71.11% in 2025 and jumped 407.91% in 2026, its largest moves.
• CRISPR Therapeutics AG's Current Deferred Revenue stood at $12.3 million in 2023, then plunged by 68.74% to $3.8 million in 2024, then soared by 310.17% to $15.8 million in 2025, then decreased by 2.71% to $15.3 million in 2026.
• The last three Current Deferred Revenue figures came in at $15.3 million (Q1 2026), $15.8 million (Q4 2025), and $1.3 million (Q3 2025), per Business Quant data.